Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference
14 oct. 2023 12h30 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical...
Metastatic Cancer Drug Market Thrives with Collaborative Innovations: Pfizer, Sanofi, and Merck Leading the Charge
15 sept. 2023 10h18 HE
|
Research and Markets
Dublin, Sept. 15, 2023 (GLOBE NEWSWIRE) -- The "Global Metastatic Cancer Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Indication, By Therapy (Targeted...
Global Precision Medicine Market Soars to $100.5 Billion by 2028, Fueled by Personalized Healthcare Demand and Technological Advancements
04 sept. 2023 10h39 HE
|
Research and Markets
Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Precision Medicine: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global precision medicine market, valued at...
Global Precision Oncology Research Report 2023: A Projected $225+ Billion Industry by 2031 - Explore Precision Oncology's Rise
04 sept. 2023 05h28 HE
|
Research and Markets
Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Global Precision Oncology Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global precision...
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September
29 août 2023 08h30 HE
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will...
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
03 août 2023 08h00 HE
|
Prelude Therapeutics, Inc.
Four lead programs on track to deliver clinical data and to inform future development plans Recent equity financing extends cash runway into 2026, enabling advancement of Prelude’s pipeline through...
ITM eröffnet weltweit größte Anlage zur Produktion von Lutetium-177 für zielgerichtete Radionuklidtherapien gegen Krebs
13 juin 2023 02h00 HE
|
ITM Isotope Technologies Munich SE
Neue Herstellungsanlage in Neufahrn bei München verzehnfacht ITMs Produktionskapazitäten Feierliche Eröffnung durch Staatsminister Dr. Florian Herrmann, Leiter der Bayerischen Staatskanzlei ...
ITM Opens World's Largest Lutetium-177 Production Facility for Targeted Radionuclide Therapies Against Cancer
13 juin 2023 02h00 HE
|
ITM Isotope Technologies Munich SE
New manufacturing plant in Neufahrn near Munich increases ITM's production capacity tenfoldCeremonial opening by Minister of State, Dr. Florian Herrmann, Head of the Bavarian State Chancellery ...
ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities
05 juin 2023 05h00 HE
|
ITM Isotope Technologies Munich SE
One of the largest private investment rounds in European biotech to-dateNet proceeds will enhance ITM’s radiopharmaceutical pipeline, bolster commercial infrastructure, expand leading...
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
08 mai 2023 08h30 HE
|
Prelude Therapeutics, Inc.
Eight abstracts presented at AACR 2023 demonstrate progress of the pipeline Cash runway unchanged, supporting operations into the fourth quarter of 2024 WILMINGTON, Del., May 08, 2023 (GLOBE...